Pulse Biosciences (NASDAQ:PLSE) Share Price Crosses Below 50 Day Moving Average – Here’s What Happened

Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $17.79 and traded as low as $16.52. Pulse Biosciences shares last traded at $17.72, with a volume of 101,693 shares changing hands.

Analysts Set New Price Targets

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a report on Friday, September 20th.

Pulse Biosciences Trading Down 16.5 %

The stock has a 50-day moving average of $17.62 and a 200 day moving average of $14.24.

Pulse Biosciences (NASDAQ:PLSE) last released its earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. During the same period last year, the firm earned ($0.19) earnings per share.

Hedge Funds Weigh In On Pulse Biosciences

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. grew its position in shares of Pulse Biosciences by 28.8% in the first quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock valued at $7,379,000 after purchasing an additional 189,227 shares in the last quarter. Cetera Advisors LLC purchased a new position in shares of Pulse Biosciences in the first quarter valued at $109,000. BNP Paribas Financial Markets grew its position in shares of Pulse Biosciences by 63.6% in the first quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company’s stock valued at $66,000 after purchasing an additional 2,952 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new position in shares of Pulse Biosciences in the first quarter valued at $88,000. Finally, Quest Partners LLC purchased a new position in shares of Pulse Biosciences in the second quarter valued at $91,000. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.